Camp4 Therapeutics Corp.(CAMP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAMP Camp4 Therapeutics Corp.

交易中 11-06 14:13:35 EST

3.87

+0.15

+4.03%

最高3.94	最低3.66	成交量5.49万
今开3.72	昨收3.72	日振幅7.53%
总市值2.43亿	流通市值1.96亿	总股本6,275万
成交额20.93万	换手率0.11%	流通股本5,071万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAMP","market":"US","secType":"STK","nameCN":"Camp4 Therapeutics Corp.","latestPrice":3.87,"timestamp":1793992398792,"preClose":3.72,"halted":0,"volume":54917,"delay":0,"changeRate":0.04032258064516126,"floatShares":50707786,"shares":62753200,"eps":-2.225,"marketStatus":"交易中","change":0.15,"latestTime":"11-06 14:13:35 EST","open":3.72,"high":3.94,"low":3.66,"amount":209252.9195579,"amplitude":0.075269,"askPrice":3.87,"askSize":100,"bidPrice":3.81,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-2.225,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1793998800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":3.72,"postHourTrading":{"tag":"盘后","latestPrice":3.72,"preClose":3.72,"latestTime":"17:52 EST","volume":333,"amount":1237.5,"timestamp":1793919132256,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.495169,"impliedVol":3.7723,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CAMP/wiki","defaultTab":"wiki","newsList":[{"id":"1190413701","title":"Camp4 Therapeutics获英国授权，启动CMP-002针对SYNGAP1相关疾病的1/2期人体临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1190413701","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190413701?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:34","pubTimestamp":1789040049,"startTime":"0","endTime":"0","summary":"Camp4 Therapeutics公司已获得英国监管部门的正式批准，将在当地开展CMP-002药物的1/2期人体临床试验。该试验针对的是患有SYNGAP1相关疾病的患者群体。此次授权标志着这家生物制药企业在推进罕见神经发育障碍治疗方案的进程中，迈出了关键性的一步。CMP-002作为一种实验性疗法，其安全性和初步疗效将在本次试验中得到系统评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4020","BK4139","CAMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173271010","title":"Camp4 Therapeutics Corp 获准通过私募二次交割募集高达5000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173271010","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173271010?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:05","pubTimestamp":1785150307,"startTime":"0","endTime":"0","summary":"Camp4 Therapeutics Corp已获得资格，可通过私募二次交割募集高达5000万美元。这一融资举措将为公司带来更多资金支持，助力其后续发展与战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAMP","BK4020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146266224","title":"Camp4 Therapeutics获澳大利亚监管批准，启动Cmp-002在SYNGAP1相关障碍患者中的首次人体临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1146266224","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146266224?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:01","pubTimestamp":1785150069,"startTime":"0","endTime":"0","summary":"Camp4 Therapeutics公司已成功获得澳大利亚监管部门的批准，得以启动Cmp-002针对SYNGAP1相关障碍患者的首次人体临床试验。这一里程碑式的进展，标志着该公司在罕见遗传性神经系统疾病治疗领域迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAMP","BK4139","BK4020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168033855","title":"Chardan资本首予Camp4 Therapeutics买入评级，目标价6.5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168033855","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168033855?lang=zh_cn&edition=full","pubTime":"2026-06-10 12:28","pubTimestamp":1781065700,"startTime":"0","endTime":"0","summary":"投资机构Chardan资本市场近日发布研报，首次覆盖生物技术公司Camp4 Therapeutics，并给予其“买入”评级。报告为该股设定的目标价格为6.5美元。\n此次覆盖标志着市场对该公司研发前景的关注。Chardan资本的分析报告通常为投资者提供专业见解与投资参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4020","BK4139","CAMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486705257","title":"单月超6亿美元，医药企业IPO规模重返疫情前水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705257","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486705257?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:34","pubTimestamp":1732527240,"startTime":"0","endTime":"0","summary":"今年以来，生物医药领域已经有30家公司IPO上市，累计融资规模超40.49亿美元，其中不乏CG Oncology、Kyverna Therapeutics等IPO规模超3亿美元的公司。在多肽类PTH1R激动剂领域，阿斯利康以总价18亿美元收购AmolytPharma，获得了处于临床3期的PTH1R激动剂eneboparatide，目前该疗法已经获得了FDA快速通道认定，另一家药企AscendisPharma的Yorvipath获得FDA批准上市，用于治疗成人慢性甲状旁腺功能减退。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-25/doc-incxhqmk8147031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4020","CAMP","NQmain","QID","UPB",".IXIC","PSQ","SQQQ","BDMD","BK4200","QLD","BK4007","ASO","BK4599","BK4539","BK4139","AVTE","SYRS","SEPN","GPCR","TQQQ","OMGA","GLYC","APGE","BK4082","TSLP","MNQmain","BK4561"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2486792160","title":"Camp4 Therapeutics Corporation2024财年第三财季实现净利润-13.48百万美元，同比减少15.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486792160","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486792160?lang=zh_cn&edition=full","pubTime":"2024-11-25 00:00","pubTimestamp":1732464021,"startTime":"0","endTime":"0","summary":"11月25日，Camp4 Therapeutics Corporation公布财报，公告显示公司2024财年第三财季净利润为-13.48百万美元，同比减少15.21%；其中营业收入为0.00美元，每股基本收益为-0.67美元。从资产负债表来看，Camp4 Therapeutics Corporation总负债18.19百万美元，其中短期债务3.28百万美元，资产负债比为1.18，流动比率为0.47。机构评级：截至2024年11月25日，当前有4家机构对Camp4 Therapeutics Corporation目标价做出预测，其中目标均价为21.36美元，其中最低目标价为17.00美元，最高目标价为27.43美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125000039a2522baf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125000039a2522baf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAMP","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2474546014","title":"美股异动 | 生物制药公司Camp4 Therapeutics(CAMP.US)登陆纳斯达克 开盘涨超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474546014","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2474546014?lang=zh_cn&edition=full","pubTime":"2024-10-12 00:15","pubTimestamp":1728663321,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，由医疗巨头Kaiser Permanente支持的生物制药公司Camp4 Therapeutics(CAMP.US)登陆纳斯达克，开盘涨超1%，报11.16美元，IPO价格为11美元。这家位于马萨诸塞州剑桥市的公司正在开发治疗多种遗传疾病的疗法。其主要候选产品CMP-CPS-001用于治疗最常见的尿素循环疾病，目前正在早期临床试验中进行评估。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1192996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","TQQQ","BK4007","CAMP","SQQQ","PSQ","ARTL","MNQmain","QLD",".IXIC","BK4139","159632","NQmain","BK1147","QID","BK4020","03086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2473174405","title":"CAMP4 Therapeutics(CAMP.US)宣布IPO计划 目标估值达2.83亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2473174405","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2473174405?lang=zh_cn&edition=full","pubTime":"2024-10-07 20:06","pubTimestamp":1728302809,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由医疗巨头Kaiser Permanente支持的生物制药公司CAMP4 Therapeutics周一表示，将在美国首次公开募股中寻求至多2.83亿美元的目标估值。CAMP4计划发行500万股股票，每股定价在14美元至16美元之间，筹资至多8,000万美元。其主要候选产品CMP-CPS-001用于治疗最常见的尿素循环疾病，目前正在早期临床试验中进行评估。CAMP4由曾在渤健和赛诺菲安万特工作的Josh mandelbrehm领导。该公司将在纳斯达克上市，代码为“CAMP”。摩根大通、Leerink Partners、Piper Sandler和William Blair是此次IPO的承销商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1190655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","CAMP","BK4020","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.camp4tx.com","stockEarnings":[{"period":"1week","weight":-0.0462},{"period":"1month","weight":-0.0606},{"period":"3month","weight":-0.1226},{"period":"6month","weight":-0.1659},{"period":"1year","weight":-0.1058},{"period":"ytd","weight":-0.3931}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"CAMP4 Therapeutics Corporation最初于2015年在特拉华州注册成立，并于2016年开始运营。他们是一家临床阶段的生物制药公司，率先发现和开发了基于RNA的调节疗法，旨在上调基因表达和恢复健康的蛋白质水平，以治疗各种遗传疾病。调节性RNA或regRNAs通过促进基因激活和抑制，在每个蛋白质编码基因的调节中起着核心作用。他们的方法旨在通过利用regRNAs的力量来扩增信使RNA或mRNA的表达，regRNAs与转录因子形成局部复合物并调节基因表达。他们专有的RNA驱动平台或RAP平台使他们能够快速系统地鉴定和表征控制每个表达基因的活性调控元件以及控制蛋白质编码基因的数万个可药物增强剂和启动子regRNA序列。","yearOnYearQuotes":[{"month":1,"riseRate":0.682927,"avgChangeRate":0.082077},{"month":2,"riseRate":0.463415,"avgChangeRate":-0.002283},{"month":3,"riseRate":0.414634,"avgChangeRate":-0.012666},{"month":4,"riseRate":0.475,"avgChangeRate":0.03701},{"month":5,"riseRate":0.55,"avgChangeRate":0.007695},{"month":6,"riseRate":0.390244,"avgChangeRate":-0.040171},{"month":7,"riseRate":0.35,"avgChangeRate":0.010243},{"month":8,"riseRate":0.55,"avgChangeRate":0.035717},{"month":9,"riseRate":0.512195,"avgChangeRate":0.024414},{"month":10,"riseRate":0.45,"avgChangeRate":0.026175},{"month":11,"riseRate":0.5,"avgChangeRate":0.04865},{"month":12,"riseRate":0.375,"avgChangeRate":-0.039343}],"exchange":"NASDAQ","name":"Camp4 Therapeutics Corp.","nameEN":"Camp4 Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Camp4 Therapeutics Corp.(CAMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Camp4 Therapeutics Corp.(CAMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Camp4 Therapeutics Corp.,CAMP,Camp4 Therapeutics Corp.股票,Camp4 Therapeutics Corp.股票老虎,Camp4 Therapeutics Corp.股票老虎国际,Camp4 Therapeutics Corp.行情,Camp4 Therapeutics Corp.股票行情,Camp4 Therapeutics Corp.股价,Camp4 Therapeutics Corp.股市,Camp4 Therapeutics Corp.股票价格,Camp4 Therapeutics Corp.股票交易,Camp4 Therapeutics Corp.股票购买,Camp4 Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Camp4 Therapeutics Corp.(CAMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Camp4 Therapeutics Corp.(CAMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}